You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

COVID 19, thrombosis, inflammation and cancer: Lessons Learned and Future Practice

  • Authors: Florian Lordick, MD, PhD; Anna Falanga, MD; James S. O'Donnell, MB, PhD, FRCPI, FRCPath; David Smadja, MD, PhD
  • CPD Released: 11/13/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/13/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, critical care specialists, and cardiologists.

The goal of this activity is to increase knowledge on the role of thrombosis and inflammation in patients with COVID-19 and implications to managing these patients, including those with cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of COVID-19 on coagulation
    • Role of thrombosis on outcomes in patients with COVID-19
  • Have greater competence related to
    • Management of thrombosis in patients with COVID-19, including patients with cancer


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Florian Lordick, MD, PhD

    Professor
    University Cancer Center Leipzig (UCCL)
    University Medicine
    Leipzig, Germany

    Disclosures

    Disclosure: Florian Lordick, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen; Astellas; Biontech; Bristol Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme; Roche; Servier; Zymeworks
    Served as a speaker or a member of a speakers bureau for: Amgen; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; Elsevier; Infomedica; Medtalks Switzerland; MedUpdate; Merck; Merck Sharp & Dohme; Promedicis; Roche; Servier; Springer; STreamUp!
    Received grants for clinical research from: Bristol Myers Squibb

  • Anna Falanga, MD

    Professor of Hematology
    University of Milan Bicocca, School of Medicine
    Chief
    Department of Immunohematology and Transfusion Medicine, Thrombosis and Hemostasis Center,
    Hospital Papa Giovanni XXIII
    Bergamo, Italy

    Disclosures

    Disclosure: Anna Falanga, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer; Pfizer; Sanofi

  • James S. O'Donnell, MB, PhD, FRCPI, FRCPath

    Professor of Vascular Biology
    Director of Irish Centre for Vascular Biology
    Royal College of Surgeons in Ireland
    Consultant Haematologist
    National Coagulation Centre
    St James' Hospital
    Dublin, Ireland

    Disclosures

    Disclosure: James S. O’Donnell, MB, PhD, FRCPI, FRCPath, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Baxter; Bayer; Bristol Myers Squibb; CSL Behring; Daiichi Sankyo; Octapharma; Pfizer; Shire; Sobi Biogen; Takeda
    Served as a speaker or a member of a speakers bureau for: Baxter; Bayer; Bristol Myers Squibb; Leo Pharma; Novo Nordisk; Octapharma; Pfizer; Roche; Shire; Sobi Biogen; Takeda
    Received grants for clinical research from: Baxalta; Baxter; Bayer; Novo Nordisk; Pfizer; Shire; Takeda

  • David Smadja, MD, PhD

    Hematology Department
    Inserm UMR-S 1140 (Team 1)
    Director of Biosurgical Research Lab (Carpentier Foundation)
    Paris Descartes University and European Georges Pompidou Hospital
    Paris, France

    Disclosures

    Disclosure: David Smadja, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Carmat; Leo Pharma
    Served as a speaker or a member of a speakers bureau for: Bayer; Bristol Myers Squibb

Editor

  • Walid Amara, MD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BIOTRONIK; Servier
    Served as a speaker or a member of a speakers bureau for: Amgen, Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

COVID 19, thrombosis, inflammation and cancer: Lessons Learned and Future Practice

Authors: Florian Lordick, MD, PhD; Anna Falanga, MD; James S. O'Donnell, MB, PhD, FRCPI, FRCPath; David Smadja, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/13/2020

Valid for credit through: 11/13/2021, 11:59 PM EST

processing....

ACE = angiotensin-converting enzyme
aPTT = activated partial thromboplastin time
AUC = area under the curve
bid = twice daily
BMI = body mass index
CI = confidence interval
CV = cardiovascular
DIC = disseminated intravascular coagulation
DOAC = direct oral anticoagulant
DVT = deep vein thrombosis
EC = endothelial cell
ECMO = extracorporeal membrane oxygenation
F = factor
G-CSF = granulocyte colony-stimulating factor
HR = hazard ratio
ICU = intensive care unit
IFN = interferon
IL = interleukin
Hs-cTnI = high-sensitivity cardiac troponin
LMWH = low-molecular-weight heparin
MCP1 = monocyte chemoattractant protein-1
OR = odds ratio
PaO2/FiO2 = ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
PAI = plasminogen activator inhibitor
PCR = polymerase chain reaction
PIC = pulmonary intravascular coagulation
po = by mouth
PT = prothrombin time
qd = once daily
ROC = receiver operating characteristics
RV = right ventricular
SpO2 = saturation of oxygen
sq = subcutaneous
tid = three times daily
TF = tissue factor
TM = thrombomodulin
TNF = tumor necrosis factor
tPA = tissue plasminogen activator
UFH = unfractionated heparin
uPA = urokinase-type plasminogen activator
uPAR = urokinase-type plasminogen activator receptor
VEGF = vascular endothelial growth factor
VTE = venous thromboembolism

« Return to: COVID 19, thrombosis, inflammation and cancer: Lessons Learned and Future Practice
  • Print